ulcerative colitis disease. Ulcerative colitis, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Patients take one daily zinc gluconate softgel from Dana Pharmaceutical Company with 40 mg of elemental zinc and capsule filler (glycerol, gelatin, and lecithin) al
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Body mass index between 18.5 and 35 ?Diagnosis of ulcerative colitis according to the patient's symptoms, tests and colonoscopy, and intestinal sample pathology Mild to moderate active form of the disease according to the Mayo questionnaire Absence of concomitant diseases not taking supplements containing zinc during the last 2 months No use of infliximab, Sinora, high dose of corticosteroids (above 40 mg), NSAIDs Not pregnant or lactating Not taking contraceptives
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of clinical symptoms. Timepoint: At the baseline (before the start of the intervention) and at the end of the intervention (60 days after taking zinc or placebo). Method of measurement: Mayo questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum level of Interlukin-6. Timepoint: At the baseline (before the start of the intervention) and at the end of the intervention (60 days after taking zinc or placebo). Method of measurement: In serum sample using ELISA kit.;Serum level of Interlukin-17. Timepoint: At the baseline (before the start of the intervention) and at the end of the intervention (60 days after taking zinc or placebo). Method of measurement: In serum sample using ELISA kit.;Serum level of TNF-a. Timepoint: At the baseline (before the start of the intervention) and at the end of the intervention (60 days after taking zinc or placebo). Method of measurement: In serum sample using ELISA kit.;Quality of life. Timepoint: At the baseline (before the start of the intervention) and at the end of the intervention (60 days after taking zinc or placebo). Method of measurement: Inflammatory Bowel Disease Quality of Life Short Questionnaire (IBDQ-9).;Serum level of Interlukin-10. Timepoint: At the baseline (before the start of the intervention) and at the end of the intervention (60 days after taking zinc or placebo). Method of measurement: In serum sample using ELISA kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohsen Masoodi
Iran University of Medical Sciences
Outcome results
None listed